Circulating angiogenic factors and the risk of adverse outcomes among Haitian women with preeclampsia

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  March, Melissa I ^a,b   Geahchan, Carl ^a   Wenger, Julia ^c   Raghuraman, Nandini ^a   Berg, Anders ^b   Haddow, Hamish ^d   McKeon, Bri Ann ^a   Narcisse, Rulx ^e   David, Jean Louis ^e   Scott, Jennifer ^a,f   Thadhani, Ravi ^c   Karumanchi, S Ananth ^a,b,g   Rana, Sarosh ^a,b,h  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Savjani Institute for Health Research   (United States)

^e Hospital Albert Schweitzer   (Haïti)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; PLACENTAL GROWTH FACTOR; PROANGIOGENIC PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; FLT1 PROTEIN, HUMAN; PGF PROTEIN, HUMAN; PLACENTA PROTEIN;

ADULT; ADVERSE OUTCOME; ARTICLE; BIRTH WEIGHT; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; ECLAMPSIA; FEMALE; GESTATIONAL AGE; HAITI; HAITIAN; HEALTH HAZARD; HOSPITAL ADMISSION; HUMAN; KIDNEY FAILURE; MATERNAL MORTALITY; NEWBORN DEATH; PREECLAMPSIA; PREGNANCY OUTCOME; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; SOLUTIO PLACENTAE; BLOOD; FETUS DEATH; NEWBORN; PATHOPHYSIOLOGY; PREGNANCY;

BIRTH WEIGHT; FEMALE; FETAL DEATH; GESTATIONAL AGE; HAITI; HUMANS; INFANT, NEWBORN; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84930619386     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126815     Document Type: Article

References (25)

1. Organization WH. World Health Report. Make every mother and child count. Geneva. 2005. PMID: 16332605
2. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99(1):159-67. PMID: 16175681
3. Morisaki N, Togoobaatar G, Vogel JP, Souza JP, Rowland Hogue CJ, Jayaratne K, et al. Risk factors for spontaneous and provider-initiated preterm delivery in high and low Human Development Index countries: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG. 2014; 121 Suppl 1:101-9. doi: 10.1111/1471-0528.12631 PMID: 24641540
4. Firoz T, Sanghvi H, Merialdi M, von Dadelszen P. Pre-eclampsia in low and middle income countries. Best practice & research Clinical obstetrics & gynaecology. 2011;25(4):537-48.
5. Bilano VL, Ota E, Ganchimeg T, Mori R, Souza JP. Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low- and middle-income countries: a WHO secondary analysis. PloS one. 2014;9(3):e91198. doi: 10.1371/journal.pone.0091198 PMID: 24657964
6. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649-58. PMID: 12618519
7. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. The New England journal of medicine. 2004;350(7):672-83. PMID: 14764923
8. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21(1):9-23. doi: 10.1080/14767050701830480 PMID: 18175241
9. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med. 2009;22(11):1021-38. doi: 10.3109/14767050902994754 PMID: 19900040
10. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med. 2011;24(10):1187-207. doi: 10.3109/14767058.2011.589932 PMID: 21827221
11. Romero R, Chaiworapongsa T. Preeclampsia: a link between trophoblastdysregulation and an antiangiogenic state. The Journal of clinical investigation. 2013;123(7):2775-7. doi: 10.1172/JCI70431 PMID: 23934119
12. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation. 2010;122(5):478-87. doi: 10.1161/CIRCULATIONAHA.109.895458 PMID: 20644016
13. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125(7):911-9. doi: 10.1161/CIRCULATIONAHA.111.054361 PMID: 22261192
14. Moore AG, Young H, Keller JM, Ojo LR, Yan J, Simas TA, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med. 2012;25(12):2651-7. doi: 10.3109/14767058.2012.713055 PMID: 22861812
15. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013;128(19):2121-31. doi: 10.1161/CIRCULATIONAHA.113.003215 PMID: 24190934
16. Raghuramana N, March MI, Hacker MR, Modesta MA, Wenger J, Narcissee R, David JL, Scott J, Rana S. Adverse maternal and fetal outcomes and deaths related to preeclampsia and eclampsia in Haiti. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health. 2014;4:279-286.
17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. Journal of biomedical informatics. 2009;42(2):377-81. doi: 10.1016/j.jbi.2008.08. 010 PMID: 18929686
18. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. American journal of obstetrics and gynecology. 2010;202(2):161e1-e11. doi: 10.1016/j.ajog.2009.09.016 PMID: 19850276
19. Rana S, Karumanchi SA, Lindheimer MD. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension. 2014;63(2):198-202. doi: 10.1161/HYPERTENSIONAHA.113.02293 PMID: 24166749
20. Chaiworapongsa T, Romero R, Korzeniewski SJ, Kusanovic JP, Soto E, Lam J, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol. 2013;208(4):287e1-e15. doi: 10.1016/j.ajog.2013.01.016 PMID: 23333542
21. Garcia-Tizon Larroca S, Tayyar A, Poon LC, Wright D, Nicolaides KH. Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks' gestation. Fetal diagnosis and therapy. 2014;36(1):9-17. doi: 10.1159/000362518 PMID: 24902880
22. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. The New England journal of medicine. 2006;355(10):992-1005. PMID: 16957146
23. American College of O, Gynecologists, Task Force on Hypertension in P. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstetrics and gynecology. 2013;122(5):1122-31. doi: 10.1097/01. AOG.0000437382. 03963.88 PMID: 24150027
24. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63(2):346-52. doi: 10.1161/HYPERTENSIONAHA.113.01787 PMID: 24166751
25. Goldenberg RL, Jones B, Griffin JB, Rouse DJ, Kamath-Rayne BD, Trivedi N, et al. Reducing maternal mortality from preeclampsia and eclampsia in low-resource countries-what should work? Acta obstetriciaet gynecologica Scandinavica. 2014;94(2):148-55. doi: 10.1111/aogs.12533 PMID: 25353716